

GENERIC PHARMASEC LIMITED

(Formerly known as Adi Rasayan Limited)

Registered Office: 7th Floor Purva Plaza, Shimpoli Signal, Near Reliance Energy,
off S.V. Road, Borivali (West), Mumbai- 400 092.

Website: www.genpharmasec.com Telephone: 8655550242

Email Id: compliance@genpharmasec.com/ info@genpharmasec.com

CIN: L24231MH1992PLC323914

Date: 13/02/2020

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject:- Outcome of Board Meeting held on Thursday, 13th February, 2020.

Ref: BSE Scrip Code: 531592

Pursuant to the provisions of Regulations 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held today i.e. Thursday, the 13th February, 2020 at 02:00 p.m. has:

1. Considered and approved the Un-Audited Financial Results along with Limited Review Report for the Quarter ended on December 31st, 2019 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Kindly take the same on your records.

Thanking You,

Yours Truly,

For **GENERIC PHARMASEC LIMITED**
(Formerly Known as Adi Rasayan Limited)


DOLLAR CHHEDA
DIRECTOR
DIN: 08490484



Encl: A/a

GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

Statement of Standalone Unaudited Results for the Quarter and Period Ended 31st December, 2019

(Rs. In Lakhs)

Particulars	Standalone					
	Quarter Ended			To The Period Ended		Year Ended
	31/12/2019 (Unaudited)	30/09/2019 (Unaudited)	31/12/2018 (Unaudited)	31/12/2019 (Unaudited)	31/12/2018 (Unaudited)	31/03/2019 (Audited)
1 Revenue from Operations	248.41	766.30	18.38	1,079.69	37.51	37.51
2 Other Income	18.10	15.88	15.26	47.82	15.27	37.50
3 Total Revenue (1 + 2)	266.51	782.18	33.64	1,127.51	52.78	75.01
4 Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	244.29	453.88	-	777.48	-	525.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(19.97)	276.95	-	237.19	-	(525.00)
Employee benefits expense	4.26	3.04	0.42	8.95	1.27	1.70
Depreciation and amortisation expense	0.14	0.12	0.01	0.34	0.02	0.02
Other expenses	9.11	7.86	29.97	30.23	34.59	44.53
Total expenses	237.83	741.85	30.40	1,054.18	35.88	46.26
5 Profit/(Loss) Before Exceptional item and Tax (3-4)	28.68	40.33	3.24	73.33	16.90	28.75
6 Exceptional items	-	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	28.68	40.33	3.24	73.33	16.90	28.75
8 Tax expense						
(1) Current Tax	18.33	-	0.61	18.33	3.22	5.65
(2) Deferred Tax	-	-	-	-	-	(0.01)
9 Profit / (Loss) from continuing operations (7 - 8)	10.34	40.33	2.63	55.00	13.68	23.11
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	10.34	40.33	2.63	55.00	13.68	23.11
14 Other Comprehensive Income;						
A (i) Items that will not be reclassified to profit or loss	(18.44)	(114.91)	2.10	(266.13)	2.10	(61.58)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	(0.54)	-	(0.54)	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/(loss) and other Comprehensive Income for the period	(8.10)	(74.57)	4.18	(211.13)	15.23	(38.47)
16 Earnings per equity share (for discontinued & continuing operations) of face value of Re. 1 each						
(a) Basic	0.00	0.02	0.12	0.03	0.44	0.00
(b) Diluted	0.00	0.01	0.04	0.01	0.15	0.00

Notes:

- The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 13th February, 2020.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The Financial results for the quarter ended on 31st Dec, 2019 have been subjected to a "Limited Review" by the statutory auditors of the Company. The Limited review report does not contain any qualification. The Limited review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.
- The provision for deferred tax will be made at the end of the year.

PLACE: MUMBAI
DATE: 13.02.2020



For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

Dollar
(DOLLAR AZAD CHHEDA)
DIRECTOR
DIN : 08490484



To
Board of Directors of
Generic Pharmasec Limited
(Formerly Known as "Adi Rasayan Limited")
7th Floor, Purva Plaza,
Off S.V. Road, Borivali (west),
Mumbai- 400092 Maharashtra


We have reviewed the accompanying statement of unaudited standalone financial results of Generic Pharmasec Limited (Formerly Known as "Adi Rasayan Limited") for the quarter ended 31st December, 2019 and the year to date results for the period from 1 April, 2019 to 31st December, 2019 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KOSHAL & ASSOCIATES
Chartered Accountants
Firm Reg.No.121233W


Koshal Maheshwari
Proprietor
M.No.043746

Place of signature: Mumbai
Date: 13.02.2020

UDIN: 20043746AAAAA04532